MedTrace Logo

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

NCT00928447 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2021-12-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effect and safety of rHuPH20 or placebo for the prevention and treatment of skin allergic reaction to nickel. The study drug and placebo will be administered by intradermal injection.

Conditions

  • Dermatitis, Allergic Contact

Interventions

DRUG

rHuPH20

0.25 milliliter (mL) Intradermal (ID) syringe push bolus injection of rHuPH20

DRUG

Placebo

0.25 mL ID syringe push bolus injection of placebo control

Sponsors & Collaborators

  • Halozyme Therapeutics

    lead INDUSTRY

Principal Investigators

  • Ikeadi M Ndukwu, M.D., MPH · Saint Anthony Memorial Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-23
Primary Completion
2009-09-13
Completion
2009-09-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00928447 on ClinicalTrials.gov